Jason Rhodes joins Atlas Venture; Kamada extends supply deal with Baxter;

@FierceBiotech: Just how big is the biosimilars business going to be in 5 years? Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Tiny biotech, trumpeting reformulation of a muscle relaxer, shotgun R&D strategy - what's not to like? $TNXP plunges. Story | Follow @JohnCFierce

@DamianFierce: There are now 245 companies developing biosimilars around the globe, according to @Reuters. Article | Follow @DamianFierce

@EmilyMFierce: New Washington player joins push for NIH funding. Story | Follow @EmilyMFierce

> We found out today that Jason Rhodes, who recently exited his position as president of Epizyme ($EPZM), is making the hop to Atlas Venture, the well-known early-stage VC group based in Boston. Release

> Israel's Kamada ($KMDA) has gained $26 million in additional revenue by extending its deal to supply Glassia to Baxter ($BAX). Release | More

> AMAG Pharmaceuticals ($AMAG) has bought its way into women's health with a $675 million acquisition for Lumara Health. More

Medical Device News

@FierceMedDev: Medtronic may revise $42.9B deal with Covidien under new tax rules. Story | Follow @FierceMedDev

@MichaelGFierce: Purdue team recreates tumor microenvironment to study #cancer nanomed delivery. More | Follow @MichaelGFierce

@VarunSaxena2: FierceMedicalDevices has learned that James V. Mazzo is on suspension as operating partner at life science VC Versant Ventures due to indictment. | Follow @VarunSaxena2

@EmilyWFierce: American Academy of Pediatrics backs IUDs as first-line choice for teens seeking long-term contraception. Article | Follow @EmilyWFierce

> Implanted pulley device could aid those with nerve damage to their hands. Story

> Court rules that FDA cannot rescind 510(k)s without notice and comment procedures. Article

Pharma News

@FiercePharma: FDA slaps cardiovascular warnings on Roche/Novartis asthma blockbuster Xolair. Story | Follow @FiercePharma

@TracyStaton: Bristol-Myers' oncology star lines up for lung cancer approval, leading the PD-1 pack. News | Follow @TracyStaton

@CarlyHFierce: Allergan buy Salix? Not so fast, say investors intent on Valeant vote. Article | Follow @CarlyHFierce

> Troubled AMAG snaps up fresh-from-bankruptcy Lumara in $1.25B deal. More

> Roche's Perjeta helps breast cancer patients live a record-setting 15.7 months longer. Story

CRO News

> Evotec lends its R&D might to the multiple sclerosis cause. More

> Catalent partners up with Cingulate on two ADHD drugs. Article

> Post-IPO Ergomed keeps rolling with its risk-sharing partnerships. Report

> AstraZeneca moves away from outsourcing, at least in IT. Item

> GVK accused of tampering with data in Indian clinical trials. Article

Biotech IT News

> Medidata stung by $4.8M wire transfer fraud. News

> NIH backs database-driven approach to neuromuscular research. Report

> The FDA commits $16M to track prescription drug use. Item

> PatientPowered.us wins PCORI clinical trial matchmaking app competition. Story

> FDA's Mini-Sentinel set to graduate on October 1. More

Animal Health News

> Merial expands NexGard plant in Brazil with $25M infusion. News

> Elanco and Dow AgroSciences team up to meet global demand for food. Article

> Avacta unveils new test for diagnosing lymphoma in dogs. Story

> Study: No differences between genetically engineered and non-GE feed on animals. More

> UN's Food and Agriculture Organization warns of new strain of avian influenza virus. Item

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.